SPRINGWORKS THERAPEUTICS INC (SWTX) Stock Price, Quote, News and Overview
NASDAQ:SWTX - Nasdaq - US85205L1070 - Common Stock - Currency: USD
SWTX Quote, Performance and Key Statistics
46.26
+0.06 (+0.13%)
The current stock price of SWTX is 46.26 USD. In the past month the price increased by 34.36%. In the past year, price increased by 13.13%.
SWTX Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 17.97 | 326.55B | ||
| AMGN | AMGEN INC | 12.81 | 142.94B | ||
| GILD | GILEAD SCIENCES INC | 12.52 | 120.65B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | N/A | 109.26B | ||
| REGN | REGENERON PHARMACEUTICALS | 11.91 | 56.98B | ||
| ARGX | ARGENX SE - ADR | 93.64 | 33.56B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 32.67B | ||
| ONC | BEIGENE LTD-ADR | 5.79 | 25.01B | ||
| BNTX | BIONTECH SE-ADR | N/A | 22.30B | ||
| NTRA | NATERA INC | N/A | 20.66B | ||
| SMMT | SUMMIT THERAPEUTICS INC | N/A | 17.79B | ||
| BIIB | BIOGEN INC | 7.47 | 17.32B |
Related stock screener links
About SWTX
Company Profile
Springworks Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the application of a medicine approach to acquiring, developing, and commercializing medicines. The company is headquartered in Stamford, Connecticut and currently employs 368 full-time employees. The company went IPO on 2019-09-13. The firm developed and is commercializing OGSIVEO (nirogacestat) as a Food and Drug Administration (FDA)-approved medicine for adults with desmoid tumors and GOMEKLI (mirdametinib) as an FDA-approved medicine for both adults and children with neurofibromatosis type I associated plexiform neurofibromas (NF1-PN). The company is also advancing a diverse portfolio of novel targeted therapy product candidates for patients with both solid tumors and hematological cancers. Brimarafenib is an investigational oral, small molecule, next-generation RAF dimer inhibitor that the Company is advancing in the clinic. SW-682 is an investigational oral, small molecule TEA Domain (TEAD), inhibitor that is evaluating in Hippo-mutant solid tumors. SW-3431 is an investigational, potentially first-in-class, small molecule activator of Protein Phosphotase 2A (PP2A), complexes.
Company Info
SPRINGWORKS THERAPEUTICS INC
100 Washington Blvd
Stamford CONNECTICUT 06902 US
CEO: Saqib Islam
Employees: 368
Phone: 12038839490
SPRINGWORKS THERAPEUTICS INC / SWTX FAQ
What is the stock price of SPRINGWORKS THERAPEUTICS INC today?
The current stock price of SWTX is 46.26 USD. The price increased by 0.13% in the last trading session.
What is the ticker symbol for SPRINGWORKS THERAPEUTICS INC stock?
The exchange symbol of SPRINGWORKS THERAPEUTICS INC is SWTX and it is listed on the Nasdaq exchange.
On which exchange is SWTX stock listed?
SWTX stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for SPRINGWORKS THERAPEUTICS INC stock?
12 analysts have analysed SWTX and the average price target is 55.95 USD. This implies a price increase of 20.96% is expected in the next year compared to the current price of 46.26. Check the SPRINGWORKS THERAPEUTICS INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is SPRINGWORKS THERAPEUTICS INC worth?
SPRINGWORKS THERAPEUTICS INC (SWTX) has a market capitalization of 3.47B USD. This makes SWTX a Mid Cap stock.
How many employees does SPRINGWORKS THERAPEUTICS INC have?
SPRINGWORKS THERAPEUTICS INC (SWTX) currently has 368 employees.
What are the support and resistance levels for SPRINGWORKS THERAPEUTICS INC (SWTX) stock?
SPRINGWORKS THERAPEUTICS INC (SWTX) has a support level at 46.25 and a resistance level at 46.27. Check the full technical report for a detailed analysis of SWTX support and resistance levels.
Is SPRINGWORKS THERAPEUTICS INC (SWTX) expected to grow?
The Revenue of SPRINGWORKS THERAPEUTICS INC (SWTX) is expected to grow by 81.68% in the next year. Check the estimates tab for more information on the SWTX EPS, Sales, EBIT and EBITDA future analyst estimates.
Should I buy SPRINGWORKS THERAPEUTICS INC (SWTX) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of SWTX, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of SWTX, evaluating the profitability, health, valuation and growth aspects
- SPRINGWORKS THERAPEUTICS INC (SWTX) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- SPRINGWORKS THERAPEUTICS INC (SWTX) Sales and EPS estimates to see what analysts future expectations are.
- SPRINGWORKS THERAPEUTICS INC (SWTX) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- SPRINGWORKS THERAPEUTICS INC (SWTX) Insider and Institutional Ownership to learn about the owners and their transactions.
- SPRINGWORKS THERAPEUTICS INC (SWTX) Stock Chart to make your own analysis
- SPRINGWORKS THERAPEUTICS INC (SWTX) Latest news and press-releases to stay up to date.
Does SPRINGWORKS THERAPEUTICS INC (SWTX) stock pay dividends?
SWTX does not pay a dividend.
When does SPRINGWORKS THERAPEUTICS INC (SWTX) report earnings?
SPRINGWORKS THERAPEUTICS INC (SWTX) will report earnings on 2025-08-05, before the market open.
What is the Price/Earnings (PE) ratio of SPRINGWORKS THERAPEUTICS INC (SWTX)?
SPRINGWORKS THERAPEUTICS INC (SWTX) does not have a PE ratio as the earnings reported over the last twelve months were negative (-3.48).
What is the Short Interest ratio of SPRINGWORKS THERAPEUTICS INC (SWTX) stock?
The outstanding short interest for SPRINGWORKS THERAPEUTICS INC (SWTX) is 10.91% of its float. Check the ownership tab for more information on the SWTX short interest.
SWTX Technical Analysis
ChartMill assigns a technical rating of 7 / 10 to SWTX. When comparing the yearly performance of all stocks, SWTX is one of the better performing stocks in the market, outperforming 87.7% of all stocks.
SWTX Fundamental Analysis
ChartMill assigns a fundamental rating of 4 / 10 to SWTX. SWTX has a great financial health rating, but its profitability evaluates not so good.
SWTX Financial Highlights
Over the last trailing twelve months SWTX reported a non-GAAP Earnings per Share(EPS) of -3.48. The EPS increased by 32.43% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -43.95% | ||
| ROE | -53.65% | ||
| Debt/Equity | 0 |
SWTX Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 73% to SWTX. The Buy consensus is the average rating of analysts ratings from 12 analysts.
For the next year, analysts expect an EPS growth of 30.49% and a revenue growth 81.68% for SWTX